DCT · ePRO · Remote

Decentralized clinical trials, without losing compliance.

Decentralized and hybrid trials bring the study to the patient, improving recruitment and retention. Done right, they do it without compromising ISO 14155 or GDPR.

ISO 14155ePRO & eConsentRemote monitoringGDPR
Decentralized clinical trials for medical devices, Eclevar MedTech

European Champion

Platinum Award 2026

Eclevar MedTech & Milo Health · xShare × EUCROF Open Call

Led by authority

Decentralized, but audit-ready.

A DCT still has to survive a Notified Body audit. Ours are designed by data and clinical-operations specialists who keep the trail intact.

Sébastien Meier

Sébastien Meier

Chief Data Officer · Biometry · 30 yrs

Endpoints, statistics and RWE; architect of the MILO EDC, 21 CFR Part 11 and real-time dashboards.

Charline Petitdemange

Charline Petitdemange

Lead Clinical Project Manager

ISO 14155 study conduct, EUDAMED registration and multi-country site monitoring across Europe.

ISO 14155ePRO / eConsentRemote monitoringGDPR

Awards, funding, accountability

Europe’s best-rated medical device CRO.

Platinum Award 2026

Platinum Award 2026

Top tier at the xShare × EUCROF Open Call, awarded to Eclevar MedTech and its Milo Health platform, presented at EUCROF 2026 in Amsterdam.

The announcement →

Co-funded by the European Union

Selected through the xShare Open Call for clinical research innovation, Horizon Europe.

xShare results →

Independently reported

Distinction confirmed by an independent third party, the CVBF, also an awardee of the xShare × EUCROF Open Call.

CVBF coverage →

The approach

Bring the trial to the patient.

Decentralized and hybrid designs replace some or all site visits with remote and connected data capture, cutting the burden on patients and sites.

01

What a DCT actually changes

A decentralized clinical trial moves elements of a study out of the traditional site: remote or home visits, telemedicine assessments, direct-to-patient logistics and connected devices. A hybrid design keeps some site visits and decentralises the rest. The aim is less burden, better recruitment and stronger retention.

02

The technology stack

DCTs run on a small set of validated tools working together.

The stack

  • eConsent for compliant, version-controlled informed consent
  • ePRO for patient-reported outcomes on the patient’s own device
  • Remote monitoring and connected devices for objective data
  • A validated EDC drawing it all into one auditable record

03

Staying compliant

Decentralisation does not relax ISO 14155 or GDPR. Consent must still be traceable and re-consent handled on protocol amendments; data must be pseudonymised and hosted compliantly; and the audit trail must be complete end to end. The design has to bake compliance in, not bolt it on.

04

Where DCT wins

DCT is strongest for post-market studies, PMCF surveys and long-term follow-up, where site visits are the main barrier to retention. We match the degree of decentralisation to the endpoints, so objective measurements stay rigorous while everything else gets easier.

DCT at a glance

Less burden, same rigour.

Hybrid
the pragmatic default
ePRO
patient-side data
ISO 14155
still applies
Retention
the real prize

Talk to a specialist

Could a decentralized design fix your recruitment?

Book a free scoping call. We tell you which parts of your study to decentralise, and how to keep the ISO 14155 and GDPR trail intact.

Book a free scoping call

Decentralize the burden, not the compliance.

An expert read tells you which elements of your study can go remote, which endpoints must stay controlled, and how to keep it all audit-ready.

Book a free scoping call

Questions we hear first

Decentralized trials, answered.

What is a decentralized clinical trial (DCT)?
A DCT moves elements of a study out of the traditional site using remote or home visits, telemedicine, direct-to-patient logistics and connected devices. A hybrid design keeps some site visits and decentralises the rest, reducing burden on patients and sites.
Do decentralized trials still have to follow ISO 14155?
Yes. Decentralisation does not relax ISO 14155 or GDPR. Consent must be traceable, data pseudonymised and compliantly hosted, and the audit trail complete, so compliance has to be designed into the study from the start.
What technology does a DCT need?
Typically eConsent for informed consent, ePRO for patient-reported outcomes on the patient’s own device, remote monitoring or connected devices for objective data, and a validated EDC that draws everything into one auditable record.
When is DCT most useful for devices?
It is strongest for post-market studies, PMCF surveys and long-term follow-up, where the burden of site visits is the main barrier to retention.

Reforming Clinical Evaluation of Medical Devices in Europe